another journal article, page-4

The interview appears to have been conducted in January or so. The had filed the IND, but not yet received approval when the article was written.

Interesting that even in the interview, Wolgen stated:
"The next phase will be to lend a commercial or trade name to the generic name afamelanotide and to position the company. We will reveal our activities over the next few months."

The question is why haven't they branded the drug and "revealed those activities over the next few months" like he said they would. Here we are almost a half year later - no word on anything.

The market is waiting for them to finally come through with their promises before they are buying this stock again. Everything is in a dead zone right now - no deliveries, no communication.

This is an inflection point and a turning point with the company. Hopefully we get something soon that will revive confidence in this company.